On June 1, 2026, Abivax SA announced that obefazimod, the company's first-in-class oral miR-124 enhancer, hit the FDA's primary endpoint in Part 1 of the pivotal ABTECT 44-week maintenance trial in moderate-to-severe ulcerative colitis, with placebo-adjusted clinical remission of roughly 40 percentage points at both the 25 mg and 50 mg once-daily doses (p<0.0001 at both). The Part 2 readout on June 29 added a refractory-patient data set that pulled in induction non-responders and re-randomized relapsers and still showed a 37.2% clinical remission rate at 50 mg in the most difficult cohort, while the exposure-adjusted malignancy and NMSC incidence rates landed inside the published ulcerative colitis background range. The combination converted a binary regulatory event into what is now a binary funding event, and on July 6, 2026, the company closed a $920 million follow-on at $125.00 per ADS to fund a solo United States launch, ending the dependency on a Big Pharma partner that the market had been pricing for nine months.
We see the equity today as a fully funded single-asset binary whose load-bearing question is no longer "does the science work" but "can the company sell the drug in the United States without dilution." The 30.83% gap to consensus price target ($165.91 versus $126.81) embeds the assumption that Abivax either executes the commercial build or sells the asset at a price that crystallizes the data, and the $920 million cash injection gives the company roughly three years of runway to pursue the former before being forced to consider the latter. The single load-bearing risk is a regulatory delay or a label that excludes induction non-responders, the cohort that produced the strongest Part 2 efficacy data and on which the company intends to lean commercially. The next data point that tests this is the H1 2026 financial print on September 21, 2026, which resets the burn rate against the new cash balance and confirms the pre-launch commercial build is funded through the targeted 2027 launch window.